LGM
RPTX

Logos Global Management’s Repare Therapeutics RPTX Stock Holding History

Logos Global Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500,000
Closed -$6.04M – 66
2023
Q3 		$6.04M Buy
+500,000
New +$5.16M 0.81% 35

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Logos Global Management's RPTX Position: Q1 2024 in Review

Logos Global Management sold out of Repare Therapeutics (RPTX) in Q1 2024, closing a stake of 600,000 shares — an estimated $4.38M sold.

Logos Global Management first reported a position in RPTX in Q2 2020 and held it in 9 quarters. The position peaked at $35.9M in Q4 2021. 71 funds tracked by Wall St. Rank hold RPTX as of Q1 2024.

  • Logos Global Management reported no remaining Repare Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Logos Global Management sold 600,000 Repare Therapeutics shares in Q1 2024, an estimated $4.38M.
  • Logos Global Management first reported a position in Repare Therapeutics in Q2 2020 and held it in 9 quarters.
  • Logos Global Management's Repare Therapeutics position peaked at $35.9M in Q4 2021.
  • 71 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2024.

Based on Logos Global Management's 13F filing for Q1 2024, filed 15 May 2024.